Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
2024年3月28日 - 4:42PM
JCN Newswire
Adelaide, AU & North Carolina, USA, Mar 28, 2024 - (ACN
Newswire) - Avance Clinical, the award-winning Australian and North
American market-leading CRO for biotechs, will attend World Vaccine
Congress in Washington DC (April 1-4, 2024) and share the latest
clinical trial client news including the Uvax Bio announcement.
(Booth #267)
Avance Clinical CEO, Yvonne Lungershausen said the World Vaccine
Congress was an important event for the company's US and Australian
teams as they continue to excel in biotech vaccine CRO
services.
Lungershausen said Avance Clinical is a mid-sized, agile, and
responsive CRO with a proven track record of swiftly advancing
high-quality clinical programs. "This makes us an ideal CRO partner
for vaccine focussed biotechs," she said. Lungershausen said the
company has had significant vaccine client successes in infectious
diseases, including COVID-19 and RSV, as well as other diseases
such as Hypertension and Psoriasis.
She said Avance Clinical is proud to be working with many
innovative vaccine biotech companies including Uvax Bio who have
just announced another milestone in their Phase I HIV study. Mary
Giffear, Uvax Bio's Director of Clinical Operations reported, "we
have completed enrollment in our Phase 1 study of the Company's
HIV-1 vaccine candidates, UVAX-1107 and UVAX-1197, and the
Australia-based trial is on schedule."
Lungershausen said Avance Clinical is focussed on accelerating drug
development for its biotech clients, from preclinical stages
through to Phase III.
"This is our GlobalReady program and we have more than 90 biotech
clients leveraging this unique, streamlined multi-region process.
With a globalized strategy, we ensure efficiency every step of the
way," she said.
"Biotechs are looking for a partner that can seamlessly help
transition them with the ability to start fast with high-quality
data that is readily accepted by the US Food and Drug
Administration (FDA) and other regulatory agencies. Our in-house
global regulatory affairs team assists biotechs to navigate
regulatory complexities with confidence and work to support our
clients with FDA, EMA and TGA submissions," she said.
"In addition, our GlobalReady Site Partnership Network of over
1,250 highly qualified sites across the United States ensures
maximum efficiency and effectiveness in our biotech's clinical
trials," she said.
Another key advantage for vaccine biotechs is that Avance Clinical
is accredited as a gene technology CRO which allows it to manage
pre-clinical and clinical trials for vaccines and GMO
therapies.
The Office of the Gene Technology Regulator (OGTR) has developed
globally compliant regulations and accreditations which are in line
with international guidelines.
Avance Clinical's Chief Scientific Officer Dr. Gabriel Kremmidiotis
said: "This means that as an OGTR accredited CRO we can support our
international biotech clients with extensive OGTR knowledge and
experience to accelerate their clinical research. Indeed, we would
argue the clarity around the OGTR regulations makes Australia one
of the most attractive destinations for Cell and Gene Technology
research," he said.
Find out more:
Learn about the GlobalReady model
For more information about the benefits of running your next study
with Avance Clinical contact us
Request a Proposal here
Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson
About Avance Clinical
Avance Clinical is the largest premium full-service Australian and
North American CRO delivering quality clinical trials, with
globally accepted data, in Australia, New Zealand and the US for
international biotechs. The company's clients are biotechs
completing Phase I to Phase III of their drug development program
that requires fast, agile, and adaptive solution-oriented clinical
research services.
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market
Leadership Award recipient for the past four years, has been
providing CRO services in the region for more than 26 years.
Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical services with their experienced
ClinicReady team right from pre-clinical through to Phase III
clinical services leveraging significant Australian Government
incentive rebates of up to 43.5% and rapid start-up regulatory
processes.
With experience across more than 120 indications, the CRO can
deliver world-class results and high-quality internationally
accepted data for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold standard
systems across all functional areas to provide clients with the
most effective processes. Medidata, Oracle, TrialHub, Certinia,
Salesforce, Zelta and Medrio are just some of the technology
partners.
www.avancecro.com
Copyright 2024 JCN Newswire . All rights reserved.